Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

Actavis Llc Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ACTAVIS LLC, and what generic and branded alternatives to ACTAVIS LLC drugs are available?

ACTAVIS LLC has twelve approved drugs.

There are two tentative approvals on ACTAVIS LLC drugs.

Summary for Actavis Llc

US Patents:	0
Tradenames:	10
Ingredients:	10
NDAs:	12
Patent Litigation for Actavis Llc:	See patent lawsuits for Actavis Llc
PTAB Cases with Actavis Llc as petitioner:	See PTAB cases with Actavis Llc as petitioner

Drugs and US Patents for Actavis Llc

+ Get email alerts for changes to this table

Subscribe to access the full database, or Free Forever Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Llc	AZACITIDINE	azacitidine	POWDER;INTRAVENOUS, SUBCUTANEOUS	208216-001	Apr 29, 2016	AP	RX	No	No		⤷ Free Forever Trial				⤷ Free Forever Trial
Actavis Llc	PEMETREXED	pemetrexed	SOLUTION;INTRAVENOUS	208419-001	Aug 21, 2020		DISCN	Yes	No		⤷ Free Forever Trial				⤷ Free Forever Trial
Actavis Llc	FLUDARABINE PHOSPHATE	fludarabine phosphate	INJECTABLE;INJECTION	203738-001	Feb 28, 2017	AP	RX	No	No		⤷ Free Forever Trial				⤷ Free Forever Trial
Actavis Llc	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	203551-001	Apr 12, 2013	AP	RX	No	No		⤷ Free Forever Trial				⤷ Free Forever Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Johnson and Johnson

Mallinckrodt

Baxter

Merck

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.